OTC Markets EXMKT - Delayed Quote USD

Panacos Pharmaceuticals, Inc. (PANC)

0.0001
0.0000
(0.00%)
At close: May 12 at 4:00:00 PM EDT
Loading Chart for PANC
  • Previous Close 0.0000
  • Open 0.0000
  • Bid --
  • Ask --
  • Day's Range 0.0000 - 0.0000
  • 52 Week Range 0.0000 - 0.0001
  • Volume 200
  • Avg. Volume 0
  • Market Cap (intraday) 321,841
  • Beta (5Y Monthly) -74.21
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0100
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Panacos Pharmaceuticals, Inc., a development stage biotechnology company, engages in the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The company's discovery technologies focus on novel targets in the virus life cycle, including virus maturation and virus fusion. Its product pipeline includes second- and third-generation programs in HIV maturation inhibition. The company was founded in 1999 and is headquartered in Watertown, Massachusetts.

41

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PANC

View More

Performance Overview: PANC

Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PANC
0.00%
S&P 500 (^GSPC)
0.64%

1-Year Return

PANC
0.00%
S&P 500 (^GSPC)
11.90%

3-Year Return

PANC
0.00%
S&P 500 (^GSPC)
48.70%

5-Year Return

PANC
50.00%
S&P 500 (^GSPC)
103.62%

Compare To: PANC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PANC

View More

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -52.62%

  • Return on Equity (ttm)

    -168.83%

  • Revenue (ttm)

    99k

  • Net Income Avi to Common (ttm)

    -35.76M

  • Diluted EPS (ttm)

    -0.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    26.89M

  • Total Debt/Equity (mrq)

    345.33%

  • Levered Free Cash Flow (ttm)

    -16.93M

Research Analysis: PANC

View More

Company Insights: PANC

Research Reports: PANC

View More

People Also Watch